Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|May 29, 2014
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agentsRodrigo E Mendes, Donald Biek, Ian A Critchley, et al.
The Journal of Antimicrobial Chemotherapy|March 5, 2003
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001Ian A Critchley, Deborah C Draghi, Daniel F Sahm, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national releaseJames A Karlowsky, Laurie J Kelly, Ian A Critchley, et al.
Diagnostic Microbiology and Infectious Disease|February 1, 2002
In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditorenJames A Karlowsky, Mark E Jones, Deborah C Draghi, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Antibacterial activity of REP8839, a new antibiotic for topical useIan A Critchley, Casey L Young, Kimberley C Stone, et al.
The Journal of Antimicrobial Chemotherapy|April 10, 2008
Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance studyGlenn S Tillotson, Deborah C Draghi, Daniel F Sahm, et al.
Diagnostic Microbiology and Infectious Disease|February 23, 2002
Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999Ian A Critchley, Daniel F Sahm, Clyde Thornsberry, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001Ian A Critchley, Renée S Blosser-Middleton, Mark E Jones, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisIan A Critchley, James A Karlowsky, Deborah C Draghi, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Longitudinal assessment of antipneumococcal susceptibility in the United StatesMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Pageof 6